Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 10/20 | 0.46 |
| ▸ | CYP11B2 | P19099 | 10/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20939398 | 0.85 | CYP11B2 (0.48) | NOTUMCYP11B2 | |
| SCHEMBL20939593 | 0.81 | MAP3K14 (0.41) | NOTUMCYP11B2 | |
| SCHEMBL22946268 | 0.78 | NOTUM (0.42) | NOTUMCYP11B2 | |
| SCHEMBL20939323 | 0.74 | NOTUM (0.56) | NOTUMCYP11B2 | |
| SCHEMBL6322481 | 0.71 | NOTUM (0.46) | NOTUMCYP11B2 | |
| SCHEMBL3269563 | 0.70 | NOTUM (0.53) | NOTUMCYP11B2 | |
| SCHEMBL7403474 | 0.70 | CYP11B2 (0.44) | NOTUMCYP11B2 | |
| SCHEMBL7414902 | 0.69 | CYP11B2 (0.43) | NOTUMCYP11B2 | |
| SCHEMBL20939373 | 0.67 | MAP3K14 (0.42) | NOTUMCYP11B2 | |
| SCHEMBL7218644 | 0.67 | NPSR1 (0.61) | NOTUMCYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11186589-B2 | Cyanoindoline derivatives as NIK inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2021-11-30 | — | — | US | disclosed |
| US-20210032267-A1 | CYANOINDOLINE DERIVATIVES AS NIK INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2021-02-04 | — | — | US | disclosed |
| EP-3478673-B1 | CYANOINDOLINE DERIVATIVES AS NIK INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2020-09-16 | — | — | EP | disclosed |
| US-20190119299-A1 | CYANOINDOLINE DERIVATIVES AS NIK INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2019-04-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210032267-A1 | CYANOINDOLINE DERIVATIVES AS NIK INHIBITORS | MAP3K14, NFKBIA, MAP3K15 | NOTUM 2525/4885CYP11B2 1589/4885 |
| US-20190119299-A1 | CYANOINDOLINE DERIVATIVES AS NIK INHIBITORS | NFKBIA, IKBKG, IKBKB | NOTUM 2554/4885CYP11B2 1810/4885 |
| US-11186589-B2 | Cyanoindoline derivatives as NIK inhibitors | MAP3K14, NFKBIA, MAP3K15 | NOTUM 2525/4885CYP11B2 1589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.